Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.56 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.56 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | MMP1 | P03956 | 2/20 | 0.56 |
| ▸ | MMP2 | P08253 | 2/20 | 0.56 |
| ▸ | MMP9 | P14780 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4342248 | 1.00 | ALDH1A1 (0.63) | ALDH1A1HTTL3MBTL1HDAC3HDAC4 | |
| SCHEMBL4332975 | 0.85 | ALDH1A1 (0.58) | ALDH1A1HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL4332978 | 0.85 | ALDH1A1 (0.58) | ALDH1A1HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL9313874 | 0.82 | L3MBTL1 (0.76) | ALDH1A1HTTL3MBTL1HDAC3HDAC4 | |
| SCHEMBL10631419 | 0.81 | TSHR (0.68) | ALDH1A1HTTL3MBTL1HDAC3HDAC4 | |
| SCHEMBL4334990 | 0.78 | KMT2A (0.54) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4334993 | 0.78 | KMT2A (0.54) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL308447 | 0.77 | L3MBTL1 (0.69) | ALDH1A1HTTL3MBTL1HDAC3HDAC4 | |
| SCHEMBL1117828 | 0.77 | L3MBTL1 (0.69) | ALDH1A1HTTL3MBTL1HDAC3HDAC4 | |
| SCHEMBL11778837 | 0.76 | GSK3B (0.87) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-04-05 | — | — | US | claimed |
| WO-2006138475-A2 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2006-12-28 | — | — | WO | claimed |
| US-6762320-B2 | MONOAMINE OXIDASE B INHIBITORS; ALZHEIMER'S DISEASE, SENILE DEMENTIA | HOFFMAN-LA ROCHE INC. | 2004-07-13 | — | — | US | claimed |
| US-20030232883-A1 | N-acylamino benzyl ether derivatives | HOFFMANN-LA ROCHE INC. | 2003-12-18 | — | — | US | claimed |
| EP-1511718-B1 | N-ACYLAMINOBENZENE DERVATIVES AS SELECTIVE MONOAMINE OXIDASE B INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-05-06 | — | — | EP | disclosed |
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2006138475-A2 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2006-12-28 | — | — | WO | disclosed |
| US-7053245-B2 | N-acylamino benzyl ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20050283019-A1 | N-acylamino benzyl ether derivatives | JOLIDON SYNESE | 2005-12-22 | — | — | US | disclosed |
| US-20040210079-A1 | N-acylamino benzyl ether derivatives | JOLIDON SYNESE | 2004-10-21 | — | — | US | disclosed |
| US-6762320-B2 | MONOAMINE OXIDASE B INHIBITORS; ALZHEIMER'S DISEASE, SENILE DEMENTIA | HOFFMAN-LA ROCHE INC. | 2004-07-13 | — | — | US | disclosed |
| US-20030232883-A1 | N-acylamino benzyl ether derivatives | HOFFMANN-LA ROCHE INC. | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232883-A1 | N-acylamino benzyl ether derivatives | MAOB, MAOA, AOC2 | ALDH1A1 606/4885HTT 995/4885L3MBTL1 1799/4885 |
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | ALDH1A1 664/4885HTT 1083/4885L3MBTL1 1079/4885 |
| US-20040210079-A1 | N-acylamino benzyl ether derivatives | MAOB, MAOA, CBR1 | ALDH1A1 583/4885HTT 868/4885L3MBTL1 1801/4885 |
| US-20050283019-A1 | N-acylamino benzyl ether derivatives | MAOB, MAOA, AOC2 | ALDH1A1 972/4885HTT 1206/4885L3MBTL1 1480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.